Our top pick for
Genetic Technologies Limited is a diagnostics & research business based in the US. Genetic Technologies shares (GENE) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$1.96 - $6.48|
|50-day moving average||$4.23|
|200-day moving average||$3.98|
|Wall St. target price||$12.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.30|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-241,647|
|Return on assets TTM||-45.42%|
|Return on equity TTM||-68.1%|
|Market capitalisation||$59 million|
TTM: trailing 12 months
There are currently 1.1 million Genetic Technologies shares held short by investors – that's known as Genetic Technologies's "short interest". This figure is 4.4% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Genetic Technologies shares can be evaluated.
Genetic Technologies's "short interest ratio" (SIR) is the quantity of Genetic Technologies shares currently shorted divided by the average quantity of Genetic Technologies shares traded daily (recently around 1.5 million). Genetic Technologies's SIR currently stands at 0.79. In other words for every 100,000 Genetic Technologies shares traded daily on the market, roughly 790 shares are currently held short.
However Genetic Technologies's short interest can also be evaluated against the total number of Genetic Technologies shares, or, against the total number of tradable Genetic Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genetic Technologies's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Genetic Technologies shares in existence, roughly 80 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genetic Technologies shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genetic Technologies.
Find out more about how you can short Genetic Technologies stock.
We're not expecting Genetic Technologies to pay a dividend over the next 12 months.
Genetic Technologies's shares were split on a 1:4 basis on 14 August 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genetic Technologies shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Genetic Technologies shares which in turn could have impacted Genetic Technologies's share price.
Over the last 12 months, Genetic Technologies's shares have ranged in value from as little as $1.96 up to $6.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genetic Technologies's is 0.8577. This would suggest that Genetic Technologies's shares are less volatile than average (for this exchange).
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.